Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.

Khan SA, Marasini A, Shrestha A, Bharadwaj HR, Abdul RHM, Dhali A, Alsakarneh S, Sharma A, Ali H, Dahiya DS

Digestive diseases and sciences8 Aug 2026Cited by 2 (Europe PMC)

PMID42570075DOI10.1007/s10620-026-10171-wPepBankPUB-42570075

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study24

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone24

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including dulaglutide was linked to less chronic diarrhea than controls: 8.9% versus 10.6%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including dulaglutide, to less chronic diarrhea than non-GLP-1 controls.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseChronic diarrhea at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic diarrhea
8.9%
GLP-1 group, 90-day landmark
Rate of chronic diarrhea
10.6%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4257007501
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including liraglutide was linked to less chronic diarrhea than controls: 8.9% versus 10.6%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including liraglutide, to less chronic diarrhea than non-GLP-1 controls.
Peptide
Liraglutide
Outcome
DecreaseChronic diarrhea at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic diarrhea
8.9%
GLP-1 group, 90-day landmark
Rate of chronic diarrhea
10.6%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4257007502
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including semaglutide was linked to less chronic diarrhea than controls: 8.9% versus 10.6%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including semaglutide, to less chronic diarrhea than non-GLP-1 controls.
Peptide
Semaglutide
Outcome
DecreaseChronic diarrhea at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic diarrhea
8.9%
GLP-1 group, 90-day landmark
Rate of chronic diarrhea
10.6%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4257007503
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including tirzepatide was linked to less chronic diarrhea than controls: 8.9% versus 10.6%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including tirzepatide, to less chronic diarrhea than non-GLP-1 controls.
Peptide
Tirzepatide
Outcome
DecreaseChronic diarrhea at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic diarrhea
8.9%
GLP-1 group, 90-day landmark
Rate of chronic diarrhea
10.6%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4257007504
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including dulaglutide was linked to less chronic constipation than controls: 19.8% versus 22.0%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including dulaglutide, to less chronic constipation than non-GLP-1 controls.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseChronic constipation at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic constipation
19.8%
GLP-1 group, 90-day landmark
Rate of chronic constipation
22%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4257007505
06HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including liraglutide was linked to less chronic constipation than controls: 19.8% versus 22.0%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including liraglutide, to less chronic constipation than non-GLP-1 controls.
Peptide
Liraglutide
Outcome
DecreaseChronic constipation at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic constipation
19.8%
GLP-1 group, 90-day landmark
Rate of chronic constipation
22%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4257007506
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including semaglutide was linked to less chronic constipation than controls: 19.8% versus 22.0%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including semaglutide, to less chronic constipation than non-GLP-1 controls.
Peptide
Semaglutide
Outcome
DecreaseChronic constipation at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic constipation
19.8%
GLP-1 group, 90-day landmark
Rate of chronic constipation
22%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4257007507
08HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including tirzepatide was linked to less chronic constipation than controls: 19.8% versus 22.0%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including tirzepatide, to less chronic constipation than non-GLP-1 controls.
Peptide
Tirzepatide
Outcome
DecreaseChronic constipation at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of chronic constipation
19.8%
GLP-1 group, 90-day landmark
Rate of chronic constipation
22%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4257007508
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including dulaglutide was linked to less abdominal pain than controls: 31.6% versus 35.8%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including dulaglutide, to less abdominal pain than non-GLP-1 controls.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAbdominal pain at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal pain
31.6%
GLP-1 group, 90-day landmark
Rate of abdominal pain
35.8%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4257007509
10HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including liraglutide was linked to less abdominal pain than controls: 31.6% versus 35.8%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including liraglutide, to less abdominal pain than non-GLP-1 controls.
Peptide
Liraglutide
Outcome
DecreaseAbdominal pain at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal pain
31.6%
GLP-1 group, 90-day landmark
Rate of abdominal pain
35.8%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4257007510
11HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including semaglutide was linked to less abdominal pain than controls: 31.6% versus 35.8%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including semaglutide, to less abdominal pain than non-GLP-1 controls.
Peptide
Semaglutide
Outcome
DecreaseAbdominal pain at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal pain
31.6%
GLP-1 group, 90-day landmark
Rate of abdominal pain
35.8%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4257007511
12HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including tirzepatide was linked to less abdominal pain than controls: 31.6% versus 35.8%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including tirzepatide, to less abdominal pain than non-GLP-1 controls.
Peptide
Tirzepatide
Outcome
DecreaseAbdominal pain at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal pain
31.6%
GLP-1 group, 90-day landmark
Rate of abdominal pain
35.8%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4257007512
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including dulaglutide was linked to less bloating/distension than controls: 8.3% versus 10.9%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including dulaglutide, to less bloating than non-GLP-1 controls.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAbdominal bloating at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal bloating/distension
8.3%
GLP-1 group, 90-day landmark
Rate of abdominal bloating/distension
10.9%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4257007513
14HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including liraglutide was linked to less bloating/distension than controls: 8.3% versus 10.9%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including liraglutide, to less bloating than non-GLP-1 controls.
Peptide
Liraglutide
Outcome
DecreaseAbdominal bloating at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal bloating/distension
8.3%
GLP-1 group, 90-day landmark
Rate of abdominal bloating/distension
10.9%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4257007514
15HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including semaglutide was linked to less bloating/distension than controls: 8.3% versus 10.9%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including semaglutide, to less bloating than non-GLP-1 controls.
Peptide
Semaglutide
Outcome
DecreaseAbdominal bloating at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal bloating/distension
8.3%
GLP-1 group, 90-day landmark
Rate of abdominal bloating/distension
10.9%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4257007515
16HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In IBS database analysis, pooled GLP-1 therapy including tirzepatide was linked to less bloating/distension than controls: 8.3% versus 10.9%.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including tirzepatide, to less bloating than non-GLP-1 controls.
Peptide
Tirzepatide
Outcome
DecreaseAbdominal bloating at 90-day landmark
Study
Homo sapiensn = 13,330
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Rate of abdominal bloating/distension
8.3%
GLP-1 group, 90-day landmark
Rate of abdominal bloating/distension
10.9%
non-GLP-1 group, 90-day landmark
Source sentences
Summary
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4257007516
17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In IBS subtype database analyses, pooled GLP-1 therapy including dulaglutide showed similar symptom reductions versus controls, particularly pain and bloating.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including dulaglutide, to similar symptom reductions versus controls across IBS subtypes.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseIBS subtype symptom reductions
Study
Homo sapiensn: not reported in source
Patients with IBS-D or IBS-C in TriNetX retrospective matched subtype cohorts
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Similar reductions were observed in IBS-D and IBS-C subtypes, particularly for abdominal pain and bloating/distension.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4257007517
18HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In IBS subtype database analyses, pooled GLP-1 therapy including liraglutide showed similar symptom reductions versus controls, particularly pain and bloating.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including liraglutide, to similar symptom reductions versus controls across IBS subtypes.
Peptide
Liraglutide
Outcome
DecreaseIBS subtype symptom reductions
Study
Homo sapiensn: not reported in source
Patients with IBS-D or IBS-C in TriNetX retrospective matched subtype cohorts
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Similar reductions were observed in IBS-D and IBS-C subtypes, particularly for abdominal pain and bloating/distension.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4257007518
19HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In IBS subtype database analyses, pooled GLP-1 therapy including semaglutide showed similar symptom reductions versus controls, particularly pain and bloating.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including semaglutide, to similar symptom reductions versus controls across IBS subtypes.
Peptide
Semaglutide
Outcome
DecreaseIBS subtype symptom reductions
Study
Homo sapiensn: not reported in source
Patients with IBS-D or IBS-C in TriNetX retrospective matched subtype cohorts
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Similar reductions were observed in IBS-D and IBS-C subtypes, particularly for abdominal pain and bloating/distension.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4257007519
20HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In IBS subtype database analyses, pooled GLP-1 therapy including tirzepatide showed similar symptom reductions versus controls, particularly pain and bloating.
In plain wordsDatabase analysis linked pooled GLP-1 therapy, including tirzepatide, to similar symptom reductions versus controls across IBS subtypes.
Peptide
Tirzepatide
Outcome
DecreaseIBS subtype symptom reductions
Study
Homo sapiensn: not reported in source
Patients with IBS-D or IBS-C in TriNetX retrospective matched subtype cohorts
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Similar reductions were observed in IBS-D and IBS-C subtypes, particularly for abdominal pain and bloating/distension.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4257007520
21HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In IBS database analysis of pooled GLP-1 therapy including dulaglutide, recurrence differences were smaller than incidence differences.
In plain wordsIn database analysis of pooled GLP-1 therapy, including dulaglutide, recurrence differences were smaller than incidence differences.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedRecurrence versus incidence differences
Study
Homo sapiensn: not reported in source
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Differences in outcome recurrence (number of instances) were smaller than differences in incidence.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4257007521
22HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In IBS database analysis of pooled GLP-1 therapy including liraglutide, recurrence differences were smaller than incidence differences.
In plain wordsIn database analysis of pooled GLP-1 therapy, including liraglutide, recurrence differences were smaller than incidence differences.
Peptide
Liraglutide
Outcome
Direction not reportedRecurrence versus incidence differences
Study
Homo sapiensn: not reported in source
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Differences in outcome recurrence (number of instances) were smaller than differences in incidence.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4257007522
23HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In IBS database analysis of pooled GLP-1 therapy including semaglutide, recurrence differences were smaller than incidence differences.
In plain wordsIn database analysis of pooled GLP-1 therapy, including semaglutide, recurrence differences were smaller than incidence differences.
Peptide
Semaglutide
Outcome
Direction not reportedRecurrence versus incidence differences
Study
Homo sapiensn: not reported in source
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Differences in outcome recurrence (number of instances) were smaller than differences in incidence.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4257007523
24HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In IBS database analysis of pooled GLP-1 therapy including tirzepatide, recurrence differences were smaller than incidence differences.
In plain wordsIn database analysis of pooled GLP-1 therapy, including tirzepatide, recurrence differences were smaller than incidence differences.
Peptide
Tirzepatide
Outcome
Direction not reportedRecurrence versus incidence differences
Study
Homo sapiensn: not reported in source
Patients with irritable bowel syndrome in the TriNetX retrospective matched cohort
Comparator
non-GLP-1 controls
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Differences in outcome recurrence (number of instances) were smaller than differences in incidence.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective cohort study using the TriNetX Research Network.
Summary · context
Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group).
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4257007524

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 5Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 4
21 Oct 2026, 18:59 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC